Orion receives first marketing authorisations for Bufomix Easyhaler® product

        Print
| Source: Orion
ORION CORPORATION      STOCK EXCHANGE RELEASE 14 APRIL 2014 at 9:30 PM
 EEST


Orion receives first marketing authorisations for Bufomix Easyhaler® product

Orion Corporation has received Irish and Hungarian marketing authorisation for
Bufomix Easyhaler®, an inhaled budesonide-formoterol combination product
indicated for asthma and chronic obstructive pulmonary disease (COPD). In this
formulation, budesonide acts as an anti-inflammatory agent
and formoterol acts as a long-acting bronchodilator. The marketing authorisation
covers two strengths (budesonide 160 µg / formoterol 4.5 µg and budesonide 320
µg / formoterol 9 µg) for the treatment of asthma and COPD in patients above 12
years.

The Irish and Hungarian marketing authorisations are the first approvals of the
EU decentralized procedures (DCP) for 22 EU countries, in which Sweden acted as
a reference member state. National approval procedure of the marketing
authorisation application is ongoing in following EU countries: Belgium,
Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Greece, Italy,
Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia,
Slovenia, Spain and Sweden. In addition, national procedure is ongoing in
Iceland, Norway and Switzerland. Orion will announce further information on
approvals in these countries in its upcoming Interim Reports.

Orion's Easyhaler® is an in-house developed dry-powder inhaler. Orion has
developed Easyhaler-adapted dry powder formulations of several well-known
generic active substances (salbutamol, beclometasone, budesonide, formoterol)
used in the treatment of asthma and COPD. At the moment under development is new
combined formulation of fluticasone-salmeterol for the treatment of asthma and
COPD.



Orion Corporation



 Timo Lappalainen     Olli Huotari
 President and CEO    SVP, Corporate Functions



Contact person:
Reijo Salonen, Senior Vice President, Research and Development, Orion
Corporation
tel. +358 50 966 3647


Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1777357]